New injection aims to stop brain bleeds in High-Risk patients

NCT ID NCT06393712

Recruiting now Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 19 times

Summary

This study tests an experimental drug called ALN-APP in 200 adults with cerebral amyloid angiopathy (CAA), a condition that causes bleeding in the brain. The drug is given via spinal injection and aims to slow disease progression by reducing new brain bleeds. Participants will be followed for up to 50 months to check safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90095, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Orange, California, 92868, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Palo Alto, California, 94304, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Sacramento, California, 95816, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

San Francisco, California, 94114, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Aurora, Colorado, 80045, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06510, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Gainesville, Florida, 32608, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Jacksonville, Florida, 32224, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Maitland, Florida, 32751, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Naples, Florida, 34105, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60612, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Lexington, Kentucky, 40504, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New Orleans, Louisiana, 70121, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02114, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Plymouth, Massachusetts, 02360, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Rochester, Minnesota, 55905, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

St Louis, Missouri, 63110, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Hackensack, New Jersey, 07601, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New York, New York, 10016, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New York, New York, 10029, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New York, New York, 10032, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

New York, New York, 10065, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Durham, North Carolina, 27705, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Canton, Ohio, 44718, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Cleveland, Ohio, 44195, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Abington, Pennsylvania, 19001, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Dallas, Texas, 75243, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Dallas, Texas, 75390, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

San Antonio, Texas, 78229, United States
Clinical Trial Site
ACTIVE_NOT_RECRUITING

Seattle, Washington, 98104, United States
Clinical Trial Site
RECRUITING

Adelaide, 5000, Australia
Clinical Trial Site
RECRUITING

Brisbane, 4029, Australia
Clinical Trial Site
RECRUITING

Heidelberg, 3084, Australia
Clinical Trial Site
RECRUITING

Nedlands, 6009, Australia
Clinical Trial Site
RECRUITING

Parkville, 3050, Australia
Clinical Trial Site
RECRUITING

Calgary, T2N 4Z6, Canada
Clinical Trial Site
RECRUITING

Hamilton, L8L 2X2, Canada
Clinical Trial Site
RECRUITING

Kelowna, V1Y 1Z9, Canada
Clinical Trial Site
RECRUITING

Moncton, E1C 2Z3, Canada
Clinical Trial Site
RECRUITING

Montreal, H3A 2B4, Canada
Clinical Trial Site
RECRUITING

Montreal, H3G 1H9, Canada
Clinical Trial Site
RECRUITING

Ottawa, K1Z 1G3, Canada
Clinical Trial Site
RECRUITING

Toronto, M3B 2S7, Canada
Clinical Trial Site
RECRUITING

Victoria, V8R 1J8, Canada
Clinical Trial Site
RECRUITING

Amsterdam, 1081 GN, Netherlands
Clinical Trial Site
RECRUITING

Leiden, 2333ZA, Netherlands
Clinical Trial Site
RECRUITING

Nijmegen, 6525 GA, Netherlands
Clinical Trial Site
RECRUITING

Bern, 3010, Switzerland
Clinical Trial Site
RECRUITING

Geneva, 1205, Switzerland
Clinical Trial Site
TERMINATED

Sankt Gallen, 9007, Switzerland
Clinical Trial Site
RECRUITING

Glasgow, G51 4TF, United Kingdom
Clinical Trial Site
ACTIVE_NOT_RECRUITING

London, SE5 8AF, United Kingdom
Clinical Trial Site
ACTIVE_NOT_RECRUITING

London, WC1N 3BG, United Kingdom

Conditions

Explore the condition pages connected to this study.

CEREBRAL AMYLOID ANGIOPATHY